Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice